3-溴-7-羟基-1-萘腈 | 550998-30-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 3-溴-7-羟基-1-萘腈
• 英文名称: 3-bromo-7-hydroxy-1-cyanonaphthalene
• 英文别名: 3-bromo-7-hydroxy-1-naphthonitrile；3-bromo-7-hydroxynaphthalene-1-carbonitrile
• CAS: 550998-30-6
• 化学式: C₁₁H₆BrNO
• 分子量: 248.079
• InChiKey: RGAMVVJGWSZBFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  412.1±25.0 °C(Predicted)
• 密度：
  1.71±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  3-溴-7-羟基-1-萘腈 在 四(三苯基膦)钯 、 C₆H₅N*HCl 、 sodium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 2.0h， 生成 3-(3-氟-4-羟基苯基)-7-羟基萘-1-甲腈
  参考文献：
  名称：

  ERβ Ligands. 3. Exploiting Two Binding Orientations of the 2-Phenylnaphthalene Scaffold To Achieve ERβ Selectivity

  摘要：

  The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERbeta were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERbeta, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.

  DOI：

  10.1021/jm058173s
• 作为产物：
  描述：

  7-羟基-1-萘甲腈 在 盐酸 、 溴 、 氯化亚锡 作用下， 以 溶剂黄146 为溶剂， 生成 3-溴-7-羟基-1-萘腈
  参考文献：
  名称：

  Substituted phenyl naphthalenes as estrogenic agents

  摘要：

  这项发明提供了具有结构的式I的雌激素受体调节剂 1 其中 R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，R 6 ，R 7 ，R 8 ，R 9 和R 10 如规范中所定义，或其药用可接受盐。

  公开号：

  US20030181519A1

文献信息

• Substituted 6-Phenyl-2-naphthols. Potent and Selective Nonsteroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Design, Synthesis, Biological Evaluation, and Pharmacokinetics
  作者：Sandrine Marchais-Oberwinkler、Patricia Kruchten、Martin Frotscher、Erika Ziegler、Alexander Neugebauer、Umadevi Bhoga、Emmanuel Bey、Ursula Müller-Vieira、Josef Messinger、Hubert Thole、Rolf W. Hartmann

  DOI：10.1021/jm800367k

  日期：2008.8.1

  concentration is mainly regulated by 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1), which catalyzes the reduction of the weak estrogen estrone (E1) to the highly potent E2. This enzyme is thus an important target for the treatment of hormone-dependent diseases. Thirty-seven novel substituted 6-phenyl-2-naphthols were synthesized and evaluated for 17beta-HSD1 inhibition, selectivity toward 17beta-HSD2

  17β-雌二醇（E2）与雌激素依赖性疾病的发生和发展有关。它的浓度主要受17beta-羟类固醇脱氢酶1型（17beta-HSD1）调节，该酶催化将弱雌激素雌酮（E1）还原为强效E2。因此，该酶是治疗激素依赖性疾病的重要靶标。合成了37种新型取代的6-苯基-2-萘酚，并评估了其对17beta-HSD1的抑制作用，对17beta-HSD2和雌激素受体（ER）α和β的选择性以及药代动力学特性。SAR研究表明，这些化合物最有可能根据结合模式B与活性位点结合，即与类固醇A环类似的6-苯基部分。虽然苯环上的取代会降低活性，
• NAPHTHYL(ETHYL) ACETAMIDES
  申请人：Liu Julie F.

  公开号：US20080280908A1

  公开（公告）日：2008-11-13

  This disclosure relates to novel melatonin analogues or naphthyl(ethyl)acetamides, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual melatoninergic agonist and serotoninergic antagonist.

  本公开涉及新型褪黑激素类似物或萘基(乙基)乙酰胺，其衍生物，药用盐，溶剂合物和水合物。本公开还提供了包含本公开化合物的组合物，并且利用这些组合物在治疗疾病和病况的方法中，通过给予双重褪黑激素受体激动剂和5-羟色胺受体拮抗剂来有益地治疗这些疾病和病况。
• J. Med. Chem. 2005, 48, 3953-3979
  作者：

  DOI：——

  日期：——
• EP1425009A4
  申请人：——

  公开号：EP1425009A4

  公开（公告）日：2006-10-25
• PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION
  申请人：Ivax Institute for Drug Research, Ltd.

  公开号：EP1425009A2

  公开（公告）日：2004-06-09